The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
Open accessAbstract
The prevalence of Alzheimer's disease (AD) is increasing rapidly, heightening the importance of finding effective preventive therapies for this devastating disease. Midlife vascular risk factors, including type 2 diabetes mellitus (T2DM), have been associated with increased risk of AD decades later and may serve as targets for AD prevention. Studies to date suggest that T2DM and hyperinsulinemia increase risk for AD, possibly through their effects on amyloid-beta metabolism and cerebrovascular dysfunction - two early findings in preclinical AD pathology. This paper reviews the evidence supporting a relationship between T2DM, hyperinsulinemia, and diabetic dyslipidemia on the development of AD, discusses DM treatment trials and their preliminary results on cognitive function, and proposes some strategies for optimizing future AD prevention trial design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a recent and surprising twist in the Alzheimer field, clinical studies have revealed that type 2 diabetes patients are at higher risk of developing AD (for reviews, see (Carlsson, 2010; Kopf and Frolich, 2009; Riederer et al., 2011)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Carlsson, 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“A few large clinical trials have shown that lifestyle interventions and antidiabetic medications, including metformin and rosiglitazone , prevent the development of T2DM in at-risk adults [101] [102] [103].”
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
Viability thresholds and the penumbra of focal ischemia
Hossmann, K. (1994) · Annals of Neurology · doi:10.1002/ana.410360404 · Cited by 1,370
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291
Cited by
Sorted by citations
Items 101–109 of 109
Neurologic and Cognitive Changes in the Elderly
McCarten, J. R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0892-6_24 · Cited by 2
Dyslipidemia: A Frequently Missed Disorder in Type 2 Diabetes Mellitus
Sattar, A. N. (2015) · Journals & Books Hosting (International Knowledge Sharing Platform) · Cited by 2
Parkinson’s Disease, Diabetes and Cognitive Impairment
Politis, M., Ashraghi, M. R., Pagano, G., Polychronis, S., & Niccolini, F. (2016) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214810666160630191119 · Cited by 2
Chatterjee, S., Bhattacharjee, R., Sinha, A., Maiti, A., Mukherjee, A., Ghosh, R., & Dubey, S. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1900_24 · Cited by 1
Pharmacological Perspective of Green Coffee Beans and their Metabolites: A Review
Tripathi, S., Mishra, N., & Mishra, N. (2022) · Current Nutrition & Food Science · doi:10.2174/1573401318666220913124027 · Cited by 1
Abramova, O. V., Zorkina, Y., Ushakova, V. M., Gryadunov, D. A., Ikonnikova, A. Y., Fedoseeva, E., Emelyanova, M., Ochneva, A., Morozova, I., Ka, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713395 · Cited by 1
Ocular and systemic vascular dysfunction in neurodegenerative disease
Mroczkowska, S. (2012) · Aston Publications Explorer (Aston University) · doi:10.48780/publications.aston.ac.uk.00016525
Assessment of Cognitive Function in Diabetic Patients – A Case-Control Study
Al-Tamimi, A. I., Aljirdabi, N. S., & Almosawi, S. (2022) · Journal of the Bahrain Medical Society · doi:10.26715/jbms.34_2022_2_2
Metadata
- Authors
- Carlsson, C. M.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Carlsson, Cynthia M.
- ORCID
- Carlsson, Cynthia M.
- Venue
- Journal of Alzheimer s Disease
- Publisher
- SAGE Publications
- Published
- 2010-05-26
- Volume
- 20
- Issue
- 3
- Pages
- 711-722
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC4235787
- OpenAlex
- W1570302318
- Cited by
- 109
- References
- 103
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 7 · 2022: 13 · 2021: 7 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 6 · 2014: 9 · 2013: 3 · 2012: 11
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Geriatric Research Education and Clinical Center
- National Institute on Aging (K23AG026752, P50AG033514)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Diabetes Mellitus, Type 2, Humans, Risk Factors, Diabetes Complications, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
